Durvalumab vs Tofacitinib

Durvalumab vs Tofacitinib: Overview

This comparison examines the pharmacological differences between Durvalumab and Tofacitinib.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Tofacitinib: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Tofacitinib — 3.2 hours.

Chemical Properties

Molecular Formula: Tofacitinib — C16H20N6O.

Molecular Weight: Tofacitinib — 312.3700 g/mol.

Type: Durvalumab — Antibody; Tofacitinib — Small molecule.